Oragenics Inc Stock Research

Market Summary

USD7.16-0.01

Delayed

-0.14%

OGEN Stock Price

OGEN RSI Chart

OGEN Valuation

Market Cap

14.0M

Price/Earnings (Trailing)

-0.86

Price/Sales (Trailing)

267.61

EV/EBITDA

Price/Free Cashflow

-0.91

OGEN Price/Sales (Trailing)

OGEN Profitability

EBT Margin

-18410.97%

Return on Equity

-122.04%

Return on Assets

-108.23%

Free Cashflow Yield

-110.03%

OGEN Fundamentals

OGEN Revenue

OGEN Earnings

Earnings (TTM)

-16.3M

Earnings Y/Y

10.63%

Earnings Q/Q

2.85%

Price Action

52 Week Range

0.109.29

(Low)(High)

Last 7 days

4942.3%

Last 30 days

4837.9%

Last 90 days

3342.3%

Trailing 12 Months

1619.1%

OGEN Financial Health

Current Ratio

9.69

OGEN Investor Care

Shares Dilution (1Y)

0.90%

Peers (Alternatives to Oragenics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	363.1B	1.2B	17.99%	7.19%	-172.5	290.49	17.64%	-57.08%
ABBV	263.1B	57.8B	-9.45%	14.91%	19.62	4.55	4.80%	77.95%
VRTX	80.0B	8.7B	8.24%	36.52%	24.45	9.2	22.03%	50.41%
REGN	78.0B	15.0B	0.10%	17.05%	14.53	5.14	21.25%	-23.23%
ALNY	28.4B	960.9M	-4.12%	67.08%	-23.99	29.51	28.24%	-41.08%
UTHR	11.8B	1.9B	-6.60%	28.83%	16.67	6.34	12.37%	52.98%
SRPT	11.3B	876.0M	-1.22%	90.74%	-15.73	12.86	35.70%	-47.34%
MID-CAP
MDGL	5.2B	504.0K	11.86%	385.71%	-19.04	2.5K	-66.53%	-15.89%
RARE	3.0B	343.4M	-0.07%	-36.01%	-4.42	8.74	-4.50%	-90.69%
BPMC	2.8B	272.3M	8.65%	-33.63%	-3.88	10.22	-18.36%	-74.56%
MRTX	2.8B	-	15.87%	-57.36%	-3.74	917.1	-	-52.72%
CPRX	1.5B	191.8M	-15.20%	185.31%	22.95	8.01	43.59%	60.82%
SMALL-CAP
MGNX	360.8M	93.0M	4.88%	-51.33%	-1.89	3.88	-19.83%	-30.37%
CRBP	17.5M	-	17.65%	-70.22%	-0.42	19.11	-77.61%	5.14%
CYTK	4.0M	-	-5.35%	37.11%	-0.01	63.29	26.15%	-23.38%

Financials for Oragenics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	NaN%	null	null	null	86,987	284,455
Operating Expenses	-2.1%	16,574,836	16,929,684	16,690,136	15,858,005	8,920,882
S&GA Expenses	8.6%	4,668,650	4,300,775	4,626,834	5,271,861	5,390,574
R&D Expenses	-5.7%	11,906,186	12,628,909	12,063,302	10,586,144	12,628,350
EBITDA	2.8%	-16,225,900.00	-16,693,284.00	-16,473,649.00	-15,654,621.00	-
EBITDA Margin	32.8%	-183.55	-273.05	-179.97	-	-
Earnings Before Taxes	2.8%	-16,278,306.00	-16,744,409.00	-16,527,063.00	-15,711,614.00	-17,828,121.00
EBT Margin	32.8%	-184.11	-273.94	-180.62	-	-
Interest Expenses	-11.3%	14,392	16,217	16,434	15,756	14,861
Net Income	2.8%	-16,278,306.00	-16,744,409.00	-16,527,063.00	-15,711,614.00	-17,828,121.00
Net Income Margin	32.8%	-184.11	-273.94	-180.62	-	-
Free Cahsflow	8.6%	-14,823,906.00	-16,226,594.00	-14,910,658.00	-13,514,088.00	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	-18.5%	15	18	22	28	31
Current Assets	-19.2%	15	18	22	28	31
Cash Equivalents	-21.9%	14	18	21	27	30
Net PPE	20.6%	0	0	0	0	0
Current Liabilities	2.6%	1	1	1	1	2
Shareholder's Equity	-20.5%	13	17	21	26	29
Retained Earnings	-2.2%	-185.26	-181.34	-177.31	-171.27	-168.98
Additional Paid-In Capital	0.8%	197	195	195	195	195
Accumulated Depreciation	-	2	-	-	-	-
Shares Outstanding	0.8%	2	2	2	2	2

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	5.0%	-15,280.24	-16,084.19	-14,779.73	-13,470.21	-14,617.20
Share Based Compensation	52.4%	1,070	702	655	1,688	1,730
Cashflow From Investing	-4.3%	-131.83	-126.40	-189.60	-43.88	-32.16
Cashflow From Financing	-16.2%	-585.76	-504.17	-229.73	23,140	34,547

Risks for OGEN

What is the probability of a big loss on OGEN?

100%

Probability that Oragenics stock will be more than 20% underwater in next one year

100%

Probability that Oragenics stock will be more than 30% underwater in next one year.

97.7%

Probability that Oragenics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does OGEN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Oragenics was unfortunately bought at previous high price.

Drawdowns

Returns for OGEN

Cumulative Returns on OGEN

-12.8%

10-Year Cumulative Returns

-4.5%

7-Year Cumulative Returns

20.1%

5-Year Cumulative Returns

150.7%

3-Year Cumulative Returns

What are the long-term rolling returns for OGEN?

FIve years rolling returns for Oragenics.

Annualized Returns

Which funds bought or sold OGEN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-01-23	LexAurum Advisors, LLC	unchanged	-	-5,745	5,255	-%
2023-01-20	Newman Dignan & Sheerar, Inc.	unchanged	-	-900	1,100	-%
2023-01-19	TSFG, LLC	sold off	-100	-1,000	-	-%
2023-01-18	Verition Fund Management LLC	sold off	-100	-3,000	-	-%
2023-01-11	Sara-Bay Financial	reduced	-36.69	-322,000	134,000	0.07%
2022-11-15	STATE STREET CORP	unchanged	-	-60,000	112,000	-%
2022-11-15	JANE STREET GROUP, LLC	added	61.09	1,000	13,000	-%
2022-11-15	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
2022-11-14	BlackRock Inc.	reduced	-0.15	-160,000	302,000	-%
2022-11-14	NORTHERN TRUST CORP	unchanged	-	-22,000	41,000	-%

Latest Funds Activity

Are funds buying OGEN calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own OGEN

No. of Funds

Oragenics News

Schedule 13G FIlings of Oragenics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 29, 2021	intracoastal capital, llc	1.6%	1,491,667	SC 13G/A
Jan 26, 2021	hernandez joseph	0%	0	SC 13D/A
Oct 08, 2020	kirk randal j	0.4%	230,792	SC 13D/A
May 15, 2020	hernandez joseph	16.6%	9,200,000	SC 13D
Mar 02, 2020	kirk randal j	9.9%	4,612,166	SC 13D/A
Feb 14, 2020	anson funds management lp	4.9%	2,422,511	SC 13G/A
Feb 11, 2020	intracoastal capital, llc	6.7%	3,333,334	SC 13G/A
Feb 10, 2020	cvi investments, inc.	4.9%	2,422,511	SC 13G/A
Jan 24, 2020	koski family lp	3.4%	1,628,419	SC 13D/A

OGEN Fair Value

Recent SEC filings of Oragenics

View All Filings

Date Filed	Form Type	Document
Jan 23, 2023	8-K	Current Report
Jan 13, 2023	S-3	S-3
Jan 03, 2023	4	Insider Trading
Dec 23, 2022	8-K	Current Report
Dec 22, 2022	8-K	Current Report
Dec 20, 2022	8-K	Current Report
Dec 19, 2022	8-K	Current Report
Dec 16, 2022	4	Insider Trading
Dec 16, 2022	8-K	Current Report
Dec 15, 2022	4	Insider Trading

Latest Insider Trading transactions for OGEN

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-12-30	KOSKI ROBERT C	sold	-4,468.66	0.1055	-42,357	-
2022-12-29	KOSKI ROBERT C	sold	-3,884.69	0.106	-36,648	-
2022-12-15	KOSKI ROBERT C	sold	-24,699.4	0.1758	-140,497	-
2022-12-14	KOSKI ROBERT C	sold	-788.025	0.175	-4,503	-
2022-12-14	KOSKI ROBERT C	sold	-4,375	0.175	-25,000	-
2022-12-09	KOSKI ROBERT C	sold	-9,612.62	0.197	-48,795	-
2022-12-08	KOSKI ROBERT C	sold	-2,607.2	0.2	-13,036	-
2022-11-30	KOSKI ROBERT C	sold	-38,220	0.1911	-200,000	-
2022-11-29	KOSKI ROBERT C	sold	-38,460	0.1923	-200,000	-
2022-06-17	Telling Fred	bought	2,884.02	0.286	10,084	-

About Oragenics

Michael O. Sullivan

www.oragenics.com

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

OGEN Income Statement

2022-09-30

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Grant revenue	$ 86,047		$ 131,521
Operating expenses:
Research and development	2,824,598	3,547,321	10,595,842	9,275,800
General and administrative	1,215,009	847,134	3,590,892	4,194,103
Total operating expenses	4,039,607	4,394,455	14,186,734	13,469,903
Loss from operations	(3,953,560)	(4,394,455)	(14,055,213)	(13,469,903)
Other income (expense):
Interest income	41,634	17,760	68,909	62,047
Interest expense	(5,228)	(7,053)	(9,290)	(10,654)
Local business tax	(489)	2	(1,469)	(1,198)
Miscellaneous income			11,333	670
Total other income, net	35,917	10,709	69,483	50,865
Loss before income taxes	(3,917,643)	(4,383,746)	(13,985,730)	(13,419,038)
Income tax benefit
Net loss	$ (3,917,643)	$ (4,383,746)	$ (13,985,730)	$ (13,419,038)
Basic and diluted net loss per share	$ (0.03)	$ (0.04)	$ (0.12)	$ (0.12)
Shares used to compute basic and diluted net loss per share	116,744,807	116,262,938	116,511,473	111,748,586

OGEN Balance Sheet

2022-09-30

Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 13,951,054	$ 27,265,703
Other receivables		6,987
Prepaid expenses and other current assets	561,952	434,699
Total current assets	14,513,006	27,707,389
Property and equipment, net	132,382	45,708
Operating lease right-of-use assets	395,435	477,882
Total assets	15,040,823	28,230,979
Current liabilities:
Accounts payable and accrued expenses	871,084	947,574
Short-term notes payable	424,924	303,416
Operating lease liabilities	201,973	194,270
Total current liabilities	1,497,981	1,445,260
Long-term liabilities:
Operating lease liabilities	204,593	299,520
Total long-term liabilities	204,593	299,520
Shareholders’ equity:
Preferred stock, no par value; 50,000,000 shares authorized; 5,417,000, and 9,417,000 Series A shares, 4,050,000 and 6,600,000 Series B shares, issued and outstanding at September 30, 2022 and December 31, 2021, respectively	1,592,723	2,656,713
Common stock, $0.001 par value; 250,000,000 and 200,000,000 shares authorized at September 30, 2022 and December 31, 2021, respectively, 117,304,809 and 116,394,806 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	117,305	116,395
Additional paid-in capital	196,888,079	194,987,219
Accumulated deficit	(185,259,858)	(171,274,128)
Total shareholders’ equity	13,338,249	26,486,199
Total liabilities and shareholders’ equity	$ 15,040,823	$ 28,230,979